Related Experiment Video
Updated: Jun 16, 2026
Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
Preclinical studies of chemotherapy using histone deacetylase inhibitors in endometrial cancer
Noriyuki Takai1, Hisashi Narahara
1Department of Obstetrics and Gynecology, Faculty of Medicine, Oita University, Hasama-machi, Yufu-shi, Oita 879-5593, Japan.
Abstract:
Because epigenetic alterations are believed to be involved in the repression of tumor suppressor genes and promotion of tumorigenesis in endometrial cancers, novel compounds endowed with a histone deacetylase (HDAC) inhibitory activity are an attractive therapeutic approach. In this review, we discuss the biologic and therapeutic effects of HDAC inhibitors (HDACIs) in treating endometrial cancer. HDACIs were able to mediate inhibition of cell growth, cell cycle arrest, apoptosis, and the expression of genes related to the malignant phenotype in a variety of endometrial cancer cell lines. Furthermore, HDACIs were able to induce the accumulation of acetylated histones in the chromatin of the p21(WAF1) gene in human endometrial carcinoma cells. In xenograft models, some HDACIs have demonstrated antitumor activity with only few side effects. In this review, we discuss the biologic and therapeutic effects of HDACIs in treating endometrial cancer, with a special focus on preclinical studies.
Insights
Histone deacetylase inhibitors (HDACIs) show promise for endometrial cancer treatment by inhibiting tumor cell growth and promoting apoptosis. Preclinical studies indicate significant antitumor activity with minimal side effects.
Area of Science:
- Oncology
- Epigenetics
- Pharmacology
Background:
- Epigenetic alterations, including tumor suppressor gene repression, are implicated in endometrial cancer development.
- Histone deacetylase inhibitors (HDACIs) represent a potential therapeutic strategy targeting these epigenetic changes.
Purpose of the Study:
- To review the biological and therapeutic effects of HDAC inhibitors in endometrial cancer treatment.
- To focus on preclinical evidence supporting the use of HDACIs for endometrial cancer.
Main Methods:
- Review of preclinical studies on HDAC inhibitors in endometrial cancer models.
- Analysis of cellular and molecular mechanisms of HDAC inhibition in cancer cell lines.
- Evaluation of xenograft model data for antitumor activity and side effects.
Main Results:
- HDACIs demonstrated inhibition of cell growth, cell cycle arrest, and apoptosis in endometrial cancer cell lines.
- HDACIs induced histone acetylation at the p21(WAF1) gene locus in human endometrial carcinoma cells.
- Preclinical xenograft models showed significant antitumor effects with a favorable safety profile for some HDACIs.
Conclusions:
- HDAC inhibitors exhibit promising preclinical efficacy against endometrial cancer through various anti-tumorigenic mechanisms.
- HDACIs represent an attractive therapeutic avenue for endometrial cancer, warranting further clinical investigation.
